Continuous infusion of highly purified factor VIII (monoclate M)
β Scribed by Sanjeet Flora; Henry Hambley; Jill Thumpston; Jane Clark
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 122 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The effectiveness of continuous infusion porcine factor VIII (PFVIII) has been evaluated in the treatment of 7 consecutive patients with factor VIII(FVIII) inhibitors. Two patients had hemophilia A and five were nonhemophiliacs with acquired FVIII inhibitors. The median pretreatment anti-porcine FVI
The inactivation of both transfusion-relevant and model viruses by modified pasteurisation (10 hours at 63Β°C in solution) has been evaluated following the established guidelines of the EU CPMP Ad Hoc Working Party on Biotechnology/ Pharmacy. This heat treatment was introduced into the manufacturing
Factor Vlll (FVIII) replacement by continuous infusion has been advocated as a costeffective method for maintaining stable plasma levels of FVlll in the hemophilia A patient during surgery or lifethreatening hemorrhage. Continuous delivery of monoclonal or recombinant FVlll concentrates to our pedia
## Minipumps may facilitate cost-effective and convenient continuous infusion (CI) therapy for severe hemophilia A. This study evaluated the in vitro sterility, ability to support bacterial growth, and specific activity stability of a recombinant factor VIII (FVIII; Bio-clateβ’, Centeon) delivered